Join
Live feed
·
PRReleasevia Quantisnow
Eli Lilly and Company logo

Lilly's oral GLP-1, Foundayo (orforglipron), demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in its largest and longest type 2 diabetes study

ByQuantisnow·Wall Street's wire, on your screen.
LLY· Eli Lilly and Company
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track LLY (Eli Lilly and Company) and more on Quantisnow.